Viemed Healthcare Toekomstige groei

Future criteriumcontroles 4/6

De verwachting is dat Viemed Healthcare de winst en omzet met respectievelijk 49.4% en 17.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 50.1% per jaar.

Belangrijke informatie

49.4%

Groei van de winst

50.1%

Groei van de winst per aandeel

Healthcare winstgroei	61.5%
Inkomstengroei	17.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	06 Dec 2023

Recente toekomstige groei-updates

Recent updates

Some Investors May Be Worried About Viemed Healthcare's (TSE:VMD) Returns On Capital

Jul 08

Does This Valuation Of Viemed Healthcare, Inc. (TSE:VMD) Imply Investors Are Overpaying?

Mar 10

These 4 Measures Indicate That Viemed Healthcare (TSE:VMD) Is Using Debt Reasonably Well

Dec 09

Shareholders May Not Be So Generous With Viemed Healthcare, Inc.'s (TSE:VMD) CEO Compensation And Here's Why

Jun 04

Viemed Healthcare (TSE:VMD) Could Easily Take On More Debt

May 18

Viemed Healthcare, Inc.'s (TSE:VMD) Stock Is Going Strong: Is the Market Following Fundamentals?

Mar 03

I Ran A Stock Scan For Earnings Growth And Viemed Healthcare (TSE:VMD) Passed With Ease

Feb 16

Viemed Healthcare (TSE:VMD) Seems To Use Debt Rather Sparingly

Feb 03

If You Had Bought Viemed Healthcare (TSE:VMD) Shares Three Years Ago You'd Have Earned 319% Returns

Jan 21

Did Viemed Healthcare, Inc. (TSE:VMD) Insiders Sell Shares?

Jan 08

Should You Rely On Viemed Healthcare's (TSE:VMD) Earnings Growth?

Dec 22

Declining Stock and Solid Fundamentals: Is The Market Wrong About Viemed Healthcare, Inc. (TSE:VMD)?

Nov 25

Winst- en omzetgroeiprognoses

TSX:VMD - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	249	N/A	20	N/A	1
12/31/2024	222	17	18	N/A	3
12/31/2023	183	11	17	N/A	3
9/30/2023	170	9	16	40	N/A
6/30/2023	156	7	11	34	N/A
3/31/2023	146	6	7	31	N/A
12/31/2022	139	6	5	28	N/A
9/30/2022	133	8	5	29	N/A
6/30/2022	127	9	0	26	N/A
3/31/2022	121	9	3	25	N/A
12/31/2021	117	9	3	22	N/A
9/30/2021	116	10	2	20	N/A
6/30/2021	120	11	10	22	N/A
3/31/2021	136	29	29	39	N/A
12/31/2020	131	32	22	35	N/A
9/30/2020	122	29	26	37	N/A
6/30/2020	108	29	24	35	N/A
3/31/2020	86	11	2	19	N/A
12/31/2019	80	9	6	19	N/A
9/30/2019	76	9	7	20	N/A
6/30/2019	73	8	8	19	N/A
3/31/2019	68	9	16	22	N/A
12/31/2018	64	10	16	22	N/A
9/30/2018	60	7	11	15	N/A
6/30/2018	56	9	10	13	N/A
3/31/2018	51	8	6	9	N/A
12/31/2017	47	8	8	12	N/A
9/30/2017	43	11	12	14	N/A
12/31/2016	31	1	N/A	6	N/A
12/31/2015	38	10	N/A	10	N/A
12/31/2014	23	9	N/A	8	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei VMD ( 49.4% per jaar) ligt boven de spaarquote ( 1.9% ).

Winst versus markt: De winst van VMD ( 49.4% per jaar) zal naar verwachting sneller groeien dan de Canadian markt ( 16.3% per jaar).

Hoge groeiwinsten: De winst van VMD zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van VMD ( 17.8% per jaar) zal naar verwachting sneller groeien dan de markt Canadian ( 7% per jaar).

Hoge groei-inkomsten: De omzet van VMD ( 17.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van VMD naar verwachting over 3 jaar hoog zal zijn

Viemed Healthcare Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Viemed Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024

Viemed Healthcare, Inc. Provides Revenue Guidance for the Third Quarter of 2024

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2024

Viemed Healthcare, Inc. Provides Earnings Guidance for the First Quarter of 2024

Consensus EPS estimates fall by 11%

Viemed Healthcare, Inc. Provides Revenue Guidance for Third Quarter of 2023

Recent updates

Viemed Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024

Viemed Healthcare, Inc. Provides Revenue Guidance for the Third Quarter of 2024

Viemed Healthcare, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2024

Viemed Healthcare, Inc., Annual General Meeting, Jun 06, 2024

Viemed Healthcare, Inc. Provides Earnings Guidance for the First Quarter of 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Is Viemed Healthcare (TSE:VMD) A Risky Investment?

Consensus EPS estimates fall by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viemed Healthcare, Inc. Provides Revenue Guidance for Third Quarter of 2023

Independent Director exercised options and sold CA$116k worth of stock

Consensus EPS estimates increase by 15%

The Returns On Capital At Viemed Healthcare (TSE:VMD) Don't Inspire Confidence

Consensus EPS estimates increase by 57%

CEO & Director exercised options and sold CA$133k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2023

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 15%

Independent Director exercised options and sold CA$135k worth of stock

Investor sentiment improves as stock rises 19%

Consensus EPS estimates fall by 26%

Full year 2022 earnings: EPS misses analyst expectations

Does Viemed Healthcare (TSE:VMD) Have A Healthy Balance Sheet?

Viemed Healthcare, Inc. Wins Complete Overruling of Appealed Office of Inspector General Claims Resolving Multiyear Process with HHS and CMS

CEO & Director exercised options and sold CA$147k worth of stock

Independent Director exercised options and sold CA$206k worth of stock

Insufficient new directors

Consensus EPS estimates increase by 58%

Viemed Healthcare, Inc. Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Does Viemed Healthcare (TSE:VMD) Have A Healthy Balance Sheet?

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Announces Earnings Guidance for the Third Quarter of 2022

Viemed Announces Management Appointments

Some Investors May Be Worried About Viemed Healthcare's (TSE:VMD) Returns On Capital

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Announces Publication of Peer-Reviewed NIVH Study Finding Treatment Reduces Healthcare Costs and Saves Lives

Viemed Healthcare, Inc.(NasdaqCM:VMD) dropped from Russell 2000 Dynamic Index

CEO & Director exercised options and sold CA$103k worth of stock

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2022

Insufficient new directors

Viemed Healthcare, Inc., Annual General Meeting, Jun 09, 2022

Consensus forecasts updated

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Provides Revenue Guidance for the First Quarter of 2022

Does This Valuation Of Viemed Healthcare, Inc. (TSE:VMD) Imply Investors Are Overpaying?

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

These 4 Measures Indicate That Viemed Healthcare (TSE:VMD) Is Using Debt Reasonably Well

Third quarter 2021 earnings released: EPS US$0.045 (vs US$0.072 in 3Q 2020)

Independent Chairman exercised options to buy CA$79k worth of stock.

Viemed Healthcare, Inc. Provides Earnings Guidance for the Third Quarter of 2021

Second quarter 2021 earnings released: EPS US$0.04 (vs US$0.50 in 2Q 2020)

Shareholders May Not Be So Generous With Viemed Healthcare, Inc.'s (TSE:VMD) CEO Compensation And Here's Why

Viemed Healthcare (TSE:VMD) Could Easily Take On More Debt

CEO & Director exercised options and sold CA$814k worth of stock

Consensus forecasts updated

First quarter 2021 earnings released: EPS US$0.043 (vs US$0.11 in 1Q 2020)

Viemed Healthcare, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021

Analysts lower EPS estimates to US$0.25

Full year 2020 earnings released: EPS US$0.81 (vs US$0.23 in FY 2019)

Earnings beat expectations, revenue disappoints

Viemed Healthcare, Inc.'s (TSE:VMD) Stock Is Going Strong: Is the Market Following Fundamentals?

I Ran A Stock Scan For Earnings Growth And Viemed Healthcare (TSE:VMD) Passed With Ease

Commonwealth Primary Care ACO and Viemed Healthcare Announce an Innovative Chronic Respiratory Care and Sleep Management Alliance